Trials / Recruiting
RecruitingNCT07441642
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
A Randomized, Double Masked, Placebo-controlled, Multicenter, Dose-range Finding Study to Assess the Efficacy and Safety of FWY003 in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 272 (estimated)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
To characterize the dose response relationship of FWY003 in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Detailed description
This study is designed as a randomized, multi-center, double-masked, prospective study to characterize the dose response relationship, efficacy and safety of FWY003.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | FWY003 | FWY003 arm participants will receive a specific dose of FWY003 |
| DRUG | Placebo | Placebo arm participants will receive placebo |
Timeline
- Start date
- 2026-03-09
- Primary completion
- 2029-08-21
- Completion
- 2029-08-22
- First posted
- 2026-03-02
- Last updated
- 2026-04-06
Locations
7 sites across 2 countries: United States, Australia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07441642. Inclusion in this directory is not an endorsement.